Brainomix has reported results from an AI-driven imaging analysis supporting a Phase II clinical trial of a neuroprotective drug candidate for acute ischemic stroke.
This website uses cookies to give our readers the best website experience. Please refer to our privacy policy to find out how we use cookies and how you can edit your preferences.
